Intellia Therapeutics Investor Presentation — April 2019

Document content

CRISPR/Cas9 -Mediated Targeted

Insertion of Human F9 Achieves

Therapeutic Circulating Protein Levels in

Mice and Non -Human Primates

Hon-Ren Huang, Ph.D.

American Society of Gene and Cell Therapy

Disclosure: Employee of Intellia Therapeutics, Inc.2Intellia Therapeutics’ Legal Disclaimer

This presentation contains “forward -looking statements” ofIntellia Therapeutics, Inc.(“Intellia”) within themeaning ofthePrivate Securities Litigation Reform

Actof1995 .These forward -looking statements include, butarenotlimited to,express orimplied statements regarding Intellia’s ability toadvance andexpand

theCRISPR/Cas 9technology todevelop human therapeutic products, aswellasourCRISPR/Cas 9intellectual property portfolio ;ourability toachieve stable

oreffective genome editing ;ourability toeffectively administer onedose ormultiple doses ofourCRISPR/Cas 9-based product candidates ;thepotential timing

andadvancement ofourpreclinical studies, including continuing non-human primate studies forourTransthyretin Amyloidosis (“ATTR”) program andother

studies forourother programs (such as,alpha -1antitrypsin deficiency (“AATD”)), andhuman clinical trials ;thetiming andpotential achievement ofmilestones

toadvance ourpipeline, including initiation ofinvestigational new drug (“IND”) -enabling studies andfiling INDs ;ourability toreplicate results achieved inour

preclinical studies, including those inourATTR, AATD, andprimary hyperoxaluria type 1(“PH1”)programs, inanyfuture studies, including human clinical

trials ;ourability togenerate data and replicate results relating toenhancements toourproprietary lipid nanoparticle (“LNP”) technology, including its

formulation andcomponents, inpreclinical orclinical studies, orthat anyenhancements willresult inanimproved product candidate profile ;thepotential

development ofourproprietary LNP-adeno -associated virus (“AAV”) hybrid delivery system toadvance ourcomplex genome editing capabilities, such as

insertion ;thepotential development ofinvivo orexvivo celltherapeutics ofalltypes using CRISPR/Cas 9technology ;ourintent togenerate andpresent

additional data fororgans beyond theliver, andadditional insertion/repair data;theintellectual property position andstrategy ofIntellia’s licensors orother

parties from which itderives rights, aswellasthird-parties andcompetitors ;actions bygovernment agencies ;ourgrowth asacompany andtheanticipated

contribution ofthemembers ofourboard ofdirectors andourexecutives toouroperations andprogress ;theimpact ofourcollaborations onourresearch and

development programs ;thepotential commercialization opportunities, including value andmarket, forourproduct candidates ;ourexpectations regarding our